Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and o...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 140; no. 8; pp. 839 - 850
Main Authors Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara F., D'Rozario, James, Owen, Carolyn J., Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Panchal, Anesh, Lu, Tong, Wu, Jenny Q., Jiang, Yanwen, Lefebure, Marcus, Boyer, Michelle, Kater, Arnon P.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 25.08.2022
American Society of Hematology
Subjects
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Bendamustine Hydrochloride
Bendamustine Hydrochloride - adverse effects
Bridged Bicyclo Compounds, Heterocyclic
Bridged Bicyclo Compounds, Heterocyclic - adverse effects
Clinical Trials and Observations
Hematology
Human health and pathology
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Life Sciences
Neoplasm, Residual
Neoplasm, Residual - drug therapy
Neoplasm, Residual - etiology
Recurrence
Rituximab
Rituximab - adverse effects
Sulfonamides
Lymphoid Neoplasia
Clinical Trials and Observations
Free Research Articles
Online AccessGet full text

Cover

Abstract The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and overall survival (OS) with venetoclax-rituximab (VenR) vs bendamustine-rituximab (BR) in relapsed/refractory (R/R) CLL. Patients were randomized to 2 years of VenR (n = 194; rituximab for the first 6 months) or 6 months of BR (n = 195). Although undetectable minimal residual disease (uMRD) was achieved more often with VenR, the long-term implications of uMRD with this fixed-duration, chemotherapy-free regimen have not been explored. We report MRD kinetics and updated outcomes with 5 years' follow-up. Survival benefits with VenR vs BR were sustained (median PFS [95% confidence interval]: 53.6 [48.4, 57.0] vs 17.0 [15.5, 21.7] months, respectively, P < .0001; 5-year OS [95% confidence interval]: 82.1% [76.4, 87.8] vs 62.2% [54.8, 69.6], P < .0001). VenR was superior to BR, regardless of cytogenetic category. VenR-treated patients with uMRD at end of treatment (EOT; n = 83) had superior OS vs those with high-MRD+ (n = 12): 3-year post-EOT survival rates were 95.3% vs 72.9% (P = .039). In those with uMRD at EOT, median time to MRD conversion was 19.4 months. Of 47 patients with documented MRD conversion, 19 developed progressive disease (PD); median time from conversion to PD was 25.2 months. A population-based logistic growth model indicated slower MRD median doubling time post-EOT with VenR (93 days) vs BR (53 days; P = 1.2 × 10−7). No new safety signals were identified. Sustained survival, uMRD benefits, and durable responses support 2-year fixed-duration VenR treatment in R/R CLL. •Two-year fixed-duration VenR offers sustained PFS, OS, and MRD benefits over BR in R/R CLL, regardless of presence of high-risk biomarkers.•Median MRD doubling time post-VenR EOT was 93 days, with 19 months from uMRD to MRD conversion and another 25 months from conversion to PD. [Display omitted]
AbstractList The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and overall survival (OS) with venetoclax-rituximab (VenR) vs bendamustine-rituximab (BR) in relapsed/refractory (R/R) CLL. Patients were randomized to 2 years of VenR (n = 194; rituximab for the first 6 months) or 6 months of BR (n = 195). Although undetectable minimal residual disease (uMRD) was achieved more often with VenR, the long-term implications of uMRD with this fixed-duration, chemotherapy-free regimen have not been explored. We report MRD kinetics and updated outcomes with 5 years’ follow-up. Survival benefits with VenR vs BR were sustained (median PFS [95% confidence interval]: 53.6 [48.4, 57.0] vs 17.0 [15.5, 21.7] months, respectively, P < .0001; 5-year OS [95% confidence interval]: 82.1% [76.4, 87.8] vs 62.2% [54.8, 69.6], P < .0001). VenR was superior to BR, regardless of cytogenetic category. VenR-treated patients with uMRD at end of treatment (EOT; n = 83) had superior OS vs those with high-MRD+ (n = 12): 3-year post-EOT survival rates were 95.3% vs 72.9% (P = .039). In those with uMRD at EOT, median time to MRD conversion was 19.4 months. Of 47 patients with documented MRD conversion, 19 developed progressive disease (PD); median time from conversion to PD was 25.2 months. A population-based logistic growth model indicated slower MRD median doubling time post-EOT with VenR (93 days) vs BR (53 days; P = 1.2 × 10−7). No new safety signals were identified. Sustained survival, uMRD benefits, and durable responses support 2-year fixed-duration VenR treatment in R/R CLL.
The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and overall survival (OS) with venetoclax-rituximab (VenR) vs bendamustine-rituximab (BR) in relapsed/refractory (R/R) CLL. Patients were randomized to 2 years of VenR (n = 194; rituximab for the first 6 months) or 6 months of BR (n = 195). Although undetectable minimal residual disease (uMRD) was achieved more often with VenR, the long-term implications of uMRD with this fixed-duration, chemotherapy-free regimen have not been explored. We report MRD kinetics and updated outcomes with 5 years' follow-up. Survival benefits with VenR vs BR were sustained (median PFS [95% confidence interval]: 53.6 [48.4, 57.0] vs 17.0 [15.5, 21.7] months, respectively, P < .0001; 5-year OS [95% confidence interval]: 82.1% [76.4, 87.8] vs 62.2% [54.8, 69.6], P < .0001). VenR was superior to BR, regardless of cytogenetic category. VenR-treated patients with uMRD at end of treatment (EOT; n = 83) had superior OS vs those with high-MRD+ (n = 12): 3-year post-EOT survival rates were 95.3% vs 72.9% (P = .039). In those with uMRD at EOT, median time to MRD conversion was 19.4 months. Of 47 patients with documented MRD conversion, 19 developed progressive disease (PD); median time from conversion to PD was 25.2 months. A population-based logistic growth model indicated slower MRD median doubling time post-EOT with VenR (93 days) vs BR (53 days; P = 1.2 × 10−7). No new safety signals were identified. Sustained survival, uMRD benefits, and durable responses support 2-year fixed-duration VenR treatment in R/R CLL. •Two-year fixed-duration VenR offers sustained PFS, OS, and MRD benefits over BR in R/R CLL, regardless of presence of high-risk biomarkers.•Median MRD doubling time post-VenR EOT was 93 days, with 19 months from uMRD to MRD conversion and another 25 months from conversion to PD. [Display omitted]
Kater and colleagues report on 5-year outcomes for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) when treated with fixed-duration venetoclax-rituximab (VenR) in a pivotal randomized trial. Over 50% of patients who completed a 3-year VenR treatment have not progressed, and median time to next treatment is 58 months. Of 43% of patients with no measurable residual disease (MRD) at completion of VenR, 39% remained MRD-negative 3 years later, emphasizing the durability of the benefits for many patients. Two-year fixed-duration VenR offers sustained PFS, OS, and MRD benefits over BR in R/R CLL, regardless of presence of high-risk biomarkers. Median MRD doubling time post-VenR EOT was 93 days, with 19 months from uMRD to MRD conversion and another 25 months from conversion to PD. The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and overall survival (OS) with venetoclax-rituximab (VenR) vs bendamustine-rituximab (BR) in relapsed/refractory (R/R) CLL. Patients were randomized to 2 years of VenR (n = 194; rituximab for the first 6 months) or 6 months of BR (n = 195). Although undetectable minimal residual disease (uMRD) was achieved more often with VenR, the long-term implications of uMRD with this fixed-duration, chemotherapy-free regimen have not been explored. We report MRD kinetics and updated outcomes with 5 years’ follow-up. Survival benefits with VenR vs BR were sustained (median PFS [95% confidence interval]: 53.6 [48.4, 57.0] vs 17.0 [15.5, 21.7] months, respectively, P < .0001; 5-year OS [95% confidence interval]: 82.1% [76.4, 87.8] vs 62.2% [54.8, 69.6], P < .0001). VenR was superior to BR, regardless of cytogenetic category. VenR-treated patients with uMRD at end of treatment (EOT; n = 83) had superior OS vs those with high-MRD+ (n = 12): 3-year post-EOT survival rates were 95.3% vs 72.9% ( P = .039). In those with uMRD at EOT, median time to MRD conversion was 19.4 months. Of 47 patients with documented MRD conversion, 19 developed progressive disease (PD); median time from conversion to PD was 25.2 months. A population-based logistic growth model indicated slower MRD median doubling time post-EOT with VenR (93 days) vs BR (53 days; P = 1.2 × 10 −7 ). No new safety signals were identified. Sustained survival, uMRD benefits, and durable responses support 2-year fixed-duration VenR treatment in R/R CLL.
The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and overall survival (OS) with venetoclax-rituximab (VenR) vs bendamustine-rituximab (BR) in relapsed/refractory (R/R) CLL. Patients were randomized to 2 years of VenR (n = 194; rituximab for the first 6 months) or 6 months of BR (n = 195). Although undetectable minimal residual disease (uMRD) was achieved more often with VenR, the long-term implications of uMRD with this fixed-duration, chemotherapy-free regimen have not been explored. We report MRD kinetics and updated outcomes with 5 years' follow-up. Survival benefits with VenR vs BR were sustained (median PFS [95% confidence interval]: 53.6 [48.4, 57.0] vs 17.0 [15.5, 21.7] months, respectively, P < .0001; 5-year OS [95% confidence interval]: 82.1% [76.4, 87.8] vs 62.2% [54.8, 69.6], P < .0001). VenR was superior to BR, regardless of cytogenetic category. VenR-treated patients with uMRD at end of treatment (EOT; n = 83) had superior OS vs those with high-MRD+ (n = 12): 3-year post-EOT survival rates were 95.3% vs 72.9% (P = .039). In those with uMRD at EOT, median time to MRD conversion was 19.4 months. Of 47 patients with documented MRD conversion, 19 developed progressive disease (PD); median time from conversion to PD was 25.2 months. A population-based logistic growth model indicated slower MRD median doubling time post-EOT with VenR (93 days) vs BR (53 days; P = 1.2 × 10-7). No new safety signals were identified. Sustained survival, uMRD benefits, and durable responses support 2-year fixed-duration VenR treatment in R/R CLL.The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and overall survival (OS) with venetoclax-rituximab (VenR) vs bendamustine-rituximab (BR) in relapsed/refractory (R/R) CLL. Patients were randomized to 2 years of VenR (n = 194; rituximab for the first 6 months) or 6 months of BR (n = 195). Although undetectable minimal residual disease (uMRD) was achieved more often with VenR, the long-term implications of uMRD with this fixed-duration, chemotherapy-free regimen have not been explored. We report MRD kinetics and updated outcomes with 5 years' follow-up. Survival benefits with VenR vs BR were sustained (median PFS [95% confidence interval]: 53.6 [48.4, 57.0] vs 17.0 [15.5, 21.7] months, respectively, P < .0001; 5-year OS [95% confidence interval]: 82.1% [76.4, 87.8] vs 62.2% [54.8, 69.6], P < .0001). VenR was superior to BR, regardless of cytogenetic category. VenR-treated patients with uMRD at end of treatment (EOT; n = 83) had superior OS vs those with high-MRD+ (n = 12): 3-year post-EOT survival rates were 95.3% vs 72.9% (P = .039). In those with uMRD at EOT, median time to MRD conversion was 19.4 months. Of 47 patients with documented MRD conversion, 19 developed progressive disease (PD); median time from conversion to PD was 25.2 months. A population-based logistic growth model indicated slower MRD median doubling time post-EOT with VenR (93 days) vs BR (53 days; P = 1.2 × 10-7). No new safety signals were identified. Sustained survival, uMRD benefits, and durable responses support 2-year fixed-duration VenR treatment in R/R CLL.
The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and overall survival (OS) with venetoclax-rituximab (VenR) vs bendamustine-rituximab (BR) in relapsed/refractory (R/R) CLL. Patients were randomized to 2 years of VenR (n = 194; rituximab for the first 6 months) or 6 months of BR (n = 195). Although undetectable minimal residual disease (uMRD) was achieved more often with VenR, the long-term implications of uMRD with this fixed-duration, chemotherapy-free regimen have not been explored. We report MRD kinetics and updated outcomes with 5 years' follow-up. Survival benefits with VenR vs BR were sustained (median PFS [95% confidence interval]: 53.6 [48.4, 57.0] vs 17.0 [15.5, 21.7] months, respectively, P < .0001; 5-year OS [95% confidence interval]: 82.1% [76.4, 87.8] vs 62.2% [54.8, 69.6], P < .0001). VenR was superior to BR, regardless of cytogenetic category. VenR-treated patients with uMRD at end of treatment (EOT; n = 83) had superior OS vs those with high-MRD+ (n = 12): 3-year post-EOT survival rates were 95.3% vs 72.9% (P = .039). In those with uMRD at EOT, median time to MRD conversion was 19.4 months. Of 47 patients with documented MRD conversion, 19 developed progressive disease (PD); median time from conversion to PD was 25.2 months. A population-based logistic growth model indicated slower MRD median doubling time post-EOT with VenR (93 days) vs BR (53 days; P = 1.2 × 10-7). No new safety signals were identified. Sustained survival, uMRD benefits, and durable responses support 2-year fixed-duration VenR treatment in R/R CLL.
Author Assouline, Sarit
de la Serna, Javier
Mellink, Clemens
Lu, Tong
Lefebure, Marcus
Kater, Arnon P.
Seymour, John F.
Wu, Jenny Q.
Boyer, Michelle
Eichhorst, Barbara F.
Jiang, Yanwen
Robak, Tadeusz
Cartron, Guillaume
Jaeger, Ulrich
D'Rozario, James
Owen, Carolyn J.
Kipps, Thomas J.
Chyla, Brenda
Panchal, Anesh
Lamanna, Nicole
Montillo, Marco
AuthorAffiliation 6 Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
5 University of Calgary, Calgary, AB, Canada
10 Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
16 Genentech, Inc., South San Francisco, CA; and
7 Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
13 Department of Human Genetics, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
9 Hospital Universitario 12 de Octubre, Madrid, Spain
17 Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands
8 Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
1 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia
4 The John Curtin School of Medical Research, Australian National University, Canberra, Australi
AuthorAffiliation_xml – name: 5 University of Calgary, Calgary, AB, Canada
– name: 14 AbbVie, North Chicago, IL
– name: 3 University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Dusseldorf (CIO ABCD), Cologne, Germany
– name: 13 Department of Human Genetics, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
– name: 1 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia
– name: 16 Genentech, Inc., South San Francisco, CA; and
– name: 17 Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands
– name: 4 The John Curtin School of Medical Research, Australian National University, Canberra, Australia
– name: 10 Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
– name: 7 Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
– name: 2 UCSD Moores Cancer Center, San Diego, CA
– name: 15 Roche Products Ltd., Welwyn Garden City, United Kingdom
– name: 12 Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
– name: 9 Hospital Universitario 12 de Octubre, Madrid, Spain
– name: 11 Department of Hematology, Centre Hospitalier Universitaire de Montpellier (UMR-CNRS 5535), Montpellier, France
– name: 6 Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
– name: 8 Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
Author_xml – sequence: 1
  givenname: John F.
  orcidid: 0000-0003-2188-6835
  surname: Seymour
  fullname: Seymour, John F.
  organization: Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia
– sequence: 2
  givenname: Thomas J.
  surname: Kipps
  fullname: Kipps, Thomas J.
  organization: UCSD Moores Cancer Center, San Diego, CA
– sequence: 3
  givenname: Barbara F.
  surname: Eichhorst
  fullname: Eichhorst, Barbara F.
  organization: University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Dusseldorf (CIO ABCD), Cologne, Germany
– sequence: 4
  givenname: James
  surname: D'Rozario
  fullname: D'Rozario, James
  organization: The John Curtin School of Medical Research, Australian National University, Canberra, Australia
– sequence: 5
  givenname: Carolyn J.
  surname: Owen
  fullname: Owen, Carolyn J.
  organization: University of Calgary, Calgary, AB, Canada
– sequence: 6
  givenname: Sarit
  surname: Assouline
  fullname: Assouline, Sarit
  organization: Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
– sequence: 7
  givenname: Nicole
  surname: Lamanna
  fullname: Lamanna, Nicole
  organization: Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
– sequence: 8
  givenname: Tadeusz
  orcidid: 0000-0002-3411-6357
  surname: Robak
  fullname: Robak, Tadeusz
  organization: Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
– sequence: 9
  givenname: Javier
  orcidid: 0000-0003-3904-1101
  surname: de la Serna
  fullname: de la Serna, Javier
  organization: Hospital Universitario 12 de Octubre, Madrid, Spain
– sequence: 10
  givenname: Ulrich
  orcidid: 0000-0001-9826-1062
  surname: Jaeger
  fullname: Jaeger, Ulrich
  organization: Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
– sequence: 11
  givenname: Guillaume
  orcidid: 0000-0003-0659-9635
  surname: Cartron
  fullname: Cartron, Guillaume
  organization: Department of Hematology, Centre Hospitalier Universitaire de Montpellier (UMR-CNRS 5535), Montpellier, France
– sequence: 12
  givenname: Marco
  surname: Montillo
  fullname: Montillo, Marco
  organization: Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
– sequence: 13
  givenname: Clemens
  surname: Mellink
  fullname: Mellink, Clemens
  organization: Department of Human Genetics, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
– sequence: 14
  givenname: Brenda
  surname: Chyla
  fullname: Chyla, Brenda
  organization: AbbVie, North Chicago, IL
– sequence: 15
  givenname: Anesh
  surname: Panchal
  fullname: Panchal, Anesh
  organization: Roche Products Ltd., Welwyn Garden City, United Kingdom
– sequence: 16
  givenname: Tong
  orcidid: 0000-0001-5899-6857
  surname: Lu
  fullname: Lu, Tong
  organization: Genentech, Inc., South San Francisco, CA
– sequence: 17
  givenname: Jenny Q.
  surname: Wu
  fullname: Wu, Jenny Q.
  organization: Genentech, Inc., South San Francisco, CA
– sequence: 18
  givenname: Yanwen
  surname: Jiang
  fullname: Jiang, Yanwen
  organization: Genentech, Inc., South San Francisco, CA
– sequence: 19
  givenname: Marcus
  surname: Lefebure
  fullname: Lefebure, Marcus
  organization: Roche Products Ltd., Welwyn Garden City, United Kingdom
– sequence: 20
  givenname: Michelle
  surname: Boyer
  fullname: Boyer, Michelle
  organization: Roche Products Ltd., Welwyn Garden City, United Kingdom
– sequence: 21
  givenname: Arnon P.
  orcidid: 0000-0003-3190-1891
  surname: Kater
  fullname: Kater, Arnon P.
  email: a.p.kater@amsterdamumc.nl
  organization: Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35605176$$D View this record in MEDLINE/PubMed
https://hal.science/hal-04547301$$DView record in HAL
BookMark eNp9kt1vFCEUxYmpsdvqu0-GR_swLZcZ5sMHk2at1mSMidFnwsCdFjMLKzCb7X8v2-2HNtEnEvidw7kcjsiB8w4JeQ3sFKDlZ8PkvTnljAMDwaB6RhYgeFswxtkBWTDG6qLqGjgkRzH-ZJkouXhBDktRMwFNvSDxwpk5WHdFZ2cwoU5qmJB--faBKmfovDYqoaF-TtqvMFLraMBJrSOas4BjUDr5cEOXfU_VmDDQ0W7RFNlTJesd3aDD5PWktkWwad7alRpekuejmiK-uluPyY-PF9-Xl0X_9dPn5XlfaFE1qRjLshm5UabTXDWsAVFhKQYoa6FE1XJUaDTXpVZN2ahGAJhK6LYadAtm6HR5TN7vfdfzsMosuhTUJNchhwg30isr_z5x9lpe-Y3sKuAMIBuc7A2un8guz3u522NVTloy2OzYt3eXBf9rxpjkykaN06Qc-jlKXtdtByBaltE3f-Z6cL5vJQNsD-jgY8zP_IAAk7vi5W3x8rH4LKmfSLRNtxXkyez0P-G7vRBzExuLQUZt0Wk0NuTfII23_xb_Brq1yLQ
CitedBy_id crossref_primary_10_1182_bloodadvances_2023011574
crossref_primary_10_1111_bjh_18418
crossref_primary_10_1007_s11912_023_01482_6
crossref_primary_10_7759_cureus_52050
crossref_primary_10_1016_S0140_6736_24_00595_6
crossref_primary_10_3960_jslrt_24014
crossref_primary_10_1182_blood_2024024790
crossref_primary_10_3390_cancers17060943
crossref_primary_10_1080_14656566_2024_2398603
crossref_primary_10_1016_S2352_3026_22_00221_6
crossref_primary_10_1016_j_annonc_2024_06_016
crossref_primary_10_1038_s41598_024_64398_6
crossref_primary_10_1111_bjh_18802
crossref_primary_10_1038_s41408_024_01001_1
crossref_primary_10_1182_bloodadvances_2023011741
crossref_primary_10_1182_hematology_2023000506
crossref_primary_10_1002_hem3_146
crossref_primary_10_1016_j_clml_2024_10_015
crossref_primary_10_1182_blood_2024026685
crossref_primary_10_3389_fimmu_2024_1482715
crossref_primary_10_3390_hematolrep16020027
crossref_primary_10_1007_s11899_023_00721_8
crossref_primary_10_1182_blood_2022016901
crossref_primary_10_1159_000533704
crossref_primary_10_1007_s00210_025_03911_8
crossref_primary_10_1016_j_htct_2023_05_006
crossref_primary_10_1080_14712598_2022_2145881
crossref_primary_10_1007_s00277_025_06200_9
crossref_primary_10_1007_s11864_023_01103_1
crossref_primary_10_3390_life13061272
crossref_primary_10_3389_fonc_2023_1112616
crossref_primary_10_3390_ijms24065802
crossref_primary_10_1056_NEJMoa2213093
crossref_primary_10_1007_s00277_023_05304_4
crossref_primary_10_1002_hem3_126
crossref_primary_10_1038_s41408_023_00870_2
crossref_primary_10_1038_s41408_022_00756_9
crossref_primary_10_1038_s41375_024_02267_x
crossref_primary_10_3390_cancers16112049
crossref_primary_10_1053_j_seminhematol_2023_11_002
crossref_primary_10_1016_S1470_2045_24_00196_7
crossref_primary_10_1177_17588359241285988
crossref_primary_10_1053_j_seminhematol_2024_02_002
crossref_primary_10_1182_bloodadvances_2023011327
crossref_primary_10_1002_ajh_27546
crossref_primary_10_1002_hem3_70065
crossref_primary_10_1001_jamaoncol_2024_2122
crossref_primary_10_1002_hon_3199
crossref_primary_10_3389_fphar_2024_1517972
crossref_primary_10_58931_cht_2024_3255
crossref_primary_10_1182_bloodadvances_2023012221
crossref_primary_10_1182_hematology_2022000343
crossref_primary_10_1182_hematology_2022000344
crossref_primary_10_1111_imj_16207
crossref_primary_10_1182_blood_2024024510
crossref_primary_10_1182_blood_2024024631
crossref_primary_10_1080_10428194_2023_2188103
crossref_primary_10_1016_j_medcle_2024_10_012
crossref_primary_10_1182_hematology_2024000656
crossref_primary_10_1080_17474086_2024_2350528
crossref_primary_10_1186_s13045_023_01469_7
crossref_primary_10_1038_s41375_022_01699_7
crossref_primary_10_1080_10428194_2024_2449214
crossref_primary_10_1016_j_leukres_2023_107372
crossref_primary_10_1007_s12185_023_03646_3
crossref_primary_10_1016_j_leukres_2024_107541
crossref_primary_10_1016_j_critrevonc_2024_104408
crossref_primary_10_1080_14740338_2025_2471508
crossref_primary_10_1002_ajh_27009
crossref_primary_10_1182_bloodadvances_2023011307
crossref_primary_10_1055_a_2260_6280
crossref_primary_10_1177_17588359241263710
crossref_primary_10_1016_j_medcli_2024_10_018
crossref_primary_10_3390_cancers15235592
crossref_primary_10_1080_14656566_2023_2218545
crossref_primary_10_1200_EDBK_390804
crossref_primary_10_3390_cancers16050980
crossref_primary_10_1001_jama_2023_1946
crossref_primary_10_1111_bjh_18833
crossref_primary_10_3390_cancers17020268
crossref_primary_10_1182_blood_2023022861
crossref_primary_10_1182_bloodadvances_2024014474
crossref_primary_10_1007_s44313_024_00038_2
crossref_primary_10_3390_cancers16152732
crossref_primary_10_3324_haematol_2022_282628
crossref_primary_10_36290_xon_2023_061
crossref_primary_10_3390_cancers16203483
crossref_primary_10_1053_j_seminhematol_2024_01_015
crossref_primary_10_1080_14737140_2024_2398483
crossref_primary_10_1002_hon_3146
crossref_primary_10_3390_cancers14194659
crossref_primary_10_1111_bjh_18946
crossref_primary_10_4103_crst_crst_233_23
crossref_primary_10_3324_haematol_2022_282116
crossref_primary_10_1016_S2152_2650_23_00326_9
crossref_primary_10_36290_xon_2023_052
crossref_primary_10_1007_s11864_023_01112_0
crossref_primary_10_3389_fonc_2023_1130617
crossref_primary_10_1007_s11899_023_00700_z
crossref_primary_10_36290_xon_2024_017
crossref_primary_10_1182_blood_2022016927
crossref_primary_10_1080_10428194_2024_2392813
crossref_primary_10_1080_10428194_2025_2466101
Cites_doi 10.1182/blood.2019001077
10.1186/s13045-021-01054-w
10.1182/blood.2019004205
10.1016/j.trecan.2016.07.001
10.18632/oncotarget.6727
10.1111/j.1365-2141.2011.09000.x
10.1182/blood-2015-09-667675
10.1038/sj.leu.2400819
10.1158/1078-0432.CCR-08-1630
10.1182/blood.2019004492
10.1182/blood-2015-08-634816
10.1182/blood-2007-07-099432
10.1056/NEJMoa1513257
10.1016/S0140-6736(10)61381-5
10.1056/NEJMoa1313984
10.1182/blood-2017-10-810044
10.1200/JCO.2017.76.6840
10.1182/blood-2007-06-093906
10.1016/S1470-2045(16)30051-1
10.1182/blood.V94.6.1848
10.1007/s00277-016-2695-x
10.1200/JCO.21.00807
10.1208/s12248-009-9112-5
10.1200/JCO.20.00948
10.1158/2159-8290.CD-18-1119
10.1182/blood-2016-05-714162
10.1038/358015a0
10.1182/blood-2018-09-873083
10.1200/JCO.2009.27.8762
10.1200/JCO.2011.36.9348
10.1200/OP.21.00258
10.1200/JCO.18.01460
10.1080/17474086.2018.1456332
10.1182/blood-2016-01-688796
10.3324/haematol.2019.239947
10.1002/ajh.24808
10.1182/blood-2017-09-806398
10.1097/HS9.0000000000000287
10.1016/S1470-2045(16)30019-5
10.1200/JCO.18.01580
10.1056/NEJMoa1713976
10.1002/hon.31_2879
10.1182/blood.2020009578
ContentType Journal Article
Copyright 2022 American Society of Hematology
2022 by The American Society of Hematology.
Attribution - NonCommercial - NoDerivatives
2022 by The American Society of Hematology. 2022
Copyright_xml – notice: 2022 American Society of Hematology
– notice: 2022 by The American Society of Hematology.
– notice: Attribution - NonCommercial - NoDerivatives
– notice: 2022 by The American Society of Hematology. 2022
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
1XC
VOOES
5PM
DOI 10.1182/blood.2021015014
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Hyper Article en Ligne (HAL)
Hyper Article en Ligne (HAL) (Open Access)
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

CrossRef

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
EndPage 850
ExternalDocumentID PMC9412011
oai_HAL_hal_04547301v1
35605176
10_1182_blood_2021015014
S0006497122006905
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
1CY
23N
2WC
34G
39C
4.4
53G
5GY
5RE
5VS
6I.
6J9
AAEDW
AAFTH
AAXUO
ABOCM
ABVKL
ACGFO
ADBBV
AENEX
AFOSN
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
EX3
F5P
FDB
FRP
GS5
GX1
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
OK1
P2P
R.V
RHF
RHI
ROL
SJN
THE
TR2
TWZ
W2D
W8F
WH7
WOQ
WOW
X7M
YHG
YKV
ZA5
0R~
AALRI
AAYXX
ACVFH
ADCNI
ADVLN
AEUPX
AFETI
AFPUW
AGCQF
AIGII
AITUG
AKBMS
AKRWK
AKYEP
CITATION
H13
CGR
CUY
CVF
ECM
EIF
NPM
7X8
1XC
VOOES
5PM
EFKBS
ID FETCH-LOGICAL-c547t-f337f2dad9c2a707154e35b1365a5482eaedc2c3ca737a7511d45c84bc81db9c3
ISSN 0006-4971
1528-0020
IngestDate Thu Aug 21 18:39:10 EDT 2025
Sat Jul 12 03:20:22 EDT 2025
Fri Jul 11 04:37:47 EDT 2025
Wed Feb 19 02:24:44 EST 2025
Thu Apr 24 23:01:18 EDT 2025
Tue Jul 01 04:29:14 EDT 2025
Fri Feb 23 02:38:32 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Lymphoid Neoplasia
Clinical Trials and Observations
Free Research Articles
Language English
License This is an open access article under the CC BY-NC-ND license.
2022 by The American Society of Hematology.
Attribution - NonCommercial - NoDerivatives: http://creativecommons.org/licenses/by-nc-nd
Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c547t-f337f2dad9c2a707154e35b1365a5482eaedc2c3ca737a7511d45c84bc81db9c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMCID: PMC9412011
ORCID 0000-0003-3190-1891
0000-0001-9826-1062
0000-0001-5899-6857
0000-0003-3904-1101
0000-0003-0659-9635
0000-0002-3411-6357
0000-0003-2188-6835
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC9412011
PMID 35605176
PQID 2668911580
PQPubID 23479
PageCount 12
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9412011
hal_primary_oai_HAL_hal_04547301v1
proquest_miscellaneous_2668911580
pubmed_primary_35605176
crossref_primary_10_1182_blood_2021015014
crossref_citationtrail_10_1182_blood_2021015014
elsevier_sciencedirect_doi_10_1182_blood_2021015014
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-08-25
20220825
PublicationDateYYYYMMDD 2022-08-25
PublicationDate_xml – month: 08
  year: 2022
  text: 2022-08-25
  day: 25
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington, DC
PublicationTitle Blood
PublicationTitleAlternate Blood
PublicationYear 2022
Publisher Elsevier Inc
American Society of Hematology
Publisher_xml – name: Elsevier Inc
– name: American Society of Hematology
References Thompson, Tam, O'Brien (bib20) 2016; 127
Hallek, Cheson, Catovsky, International Workshop on Chronic Lymphocytic Leukemia (bib31) 2008; 111
Guo, Lu, Galanina (bib21) 2016; 7
Thompson, Srivastava, Peterson (bib6) 2019; 134
Kwok, Rawstron, Varghese (bib7) 2016; 128
Al-Sawaf, Zhang, Lu (bib32) 2021; 39
Ma, Seymour, Brander (bib42) 2021; 138
Eichhorst, Fink, Bahlo, German CLL Study Group (GCLLSG) (bib36) 2016; 17
O'Brien, Furman, Coutre (bib40) 2018; 131
Blombery, Thompson, Nguyen (bib43) 2020; 135
Brem, O'Brien (bib45) 2022; 18
Baliakas, Jeromin, Iskas, ERIC, the European Research Initiative on CLL (bib18) 2019; 133
Blombery, Anderson, Gong (bib44) 2019; 9
Stilgenbauer, Eichhorst, Schetelig (bib26) 2018; 36
Bergstrand, Karlsson (bib33) 2009; 11
Böttcher, Ritgen, Fischer (bib3) 2012; 30
Hallek, Cheson, Catovsky (bib4) 2018; 131
Wu, Seymour, Eichhorst (bib41) 2021; 5
Delgado, Espinet, Oliveira, Grupo Español de Citogenetica Hematologica (bib14) 2012; 157
Kater, Seymour, Hillmen (bib29) 2019; 37
Wierda, Allan, Siddiqi (bib38) 2021; 39
Seymour, Kipps, Eichhorst (bib30) 2018; 378
Hallek, Fischer, Fingerle-Rowson, German Chronic Lymphocytic Leukaemia Study Group (bib15) 2010; 376
Seymour (bib34) 2016; 95
Moia, Diop, Favini, Kodipad, Gaidano (bib11) 2018; 11
Lane (bib23) 1992; 358
European Medicines Agency,. Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man—condition specific guidance. Vol. Rev. 2. Ref number: EMA/CHMP/703715/2012; 2016. https://www.ema.europa.eu/en/documents/scientific-guideline/evaluation-anticancer-medicinal-products-man-appendix-4-condition-specific-guidance-rev2_en.pdf. Accessed 25 May 2022.
Goede, Fischer, Busch (bib37) 2014; 370
Anderson, Deng, Seymour (bib27) 2016; 127
Kater, Wu, Kipps (bib5) 2020; 38
Cory, Roberts, Colman, Adams (bib10) 2016; 2
Rossi, Cerri, Deambrogi (bib25) 2009; 15
Fürstenau, De Silva, Eichhorst, Hallek (bib9) 2019; 3
Zenz, Eichhorst, Busch (bib24) 2010; 28
Neilson, Auer, White (bib39) 1997; 11
Kujawski, Ouillette, Erba (bib16) 2008; 112
Leeksma, Baliakas, Moysiadis (bib17) 2021; 106
Roberts, Davids, Pagel (bib35) 2016; 374
Thompson, Wierda (bib8) 2016; 127
Stilgenbauer, Eichhorst, Schetelig (bib13) 2016; 17
Crombie, Davids (bib19) 2017; 92
Hamblin, Davis, Gardiner, Oscier, Stevenson (bib12) 1999; 94
Tausch, Schneider, Robrecht (bib28) 2020; 135
Patel, Pagel (bib1) 2021; 14
Sharman, Coutre, Furman (bib22) 2019; 37
Seymour (2022082515224507900_B34) 2016; 95
Blombery (2022082515224507900_B44) 2019; 9
Kujawski (2022082515224507900_B16) 2008; 112
Kater (2022082515224507900_B5) 2020; 38
Delgado (2022082515224507900_B14) 2012; 157
Lane (2022082515224507900_B23) 1992; 358
Anderson (2022082515224507900_B27) 2016; 127
O’Brien (2022082515224507900_B40) 2018; 131
Moia (2022082515224507900_B11) 2018; 11
Sharman (2022082515224507900_B22) 2019; 37
Seymour (2022082515224507900_B30) 2018; 378
Neilson (2022082515224507900_B39) 1997; 11
Roberts (2022082515224507900_B35) 2016; 374
Goede (2022082515224507900_B37) 2014; 370
Guo (2022082515224507900_B21) 2016; 7
Zenz (2022082515224507900_B24) 2010; 28
Stilgenbauer (2022082515224507900_B26) 2018; 36
Crombie (2022082515224507900_B19) 2017; 92
Wierda (2022082515224507900_B38) 2021; 39
Cory (2022082515224507900_B10) 2016; 2
Wu (2022082515224507900_B41) 2021; 5
Patel (2022082515224507900_B1) 2021; 14
European Medicines Agency (2022082515224507900_B2) 2016
Thompson (2022082515224507900_B20) 2016; 127
Tausch (2022082515224507900_B28) 2020; 135
Brem (2022082515224507900_B45) 2022; 18
Ma (2022082515224507900_B42) 2021; 138
Stilgenbauer (2022082515224507900_B13) 2016; 17
Al-Sawaf (2022082515224507900_B32) 2021; 39
Böttcher (2022082515224507900_B3) 2012; 30
Eichhorst (2022082515224507900_B36) 2016; 17
Hamblin (2022082515224507900_B12) 1999; 94
Rossi (2022082515224507900_B25) 2009; 15
Bergstrand (2022082515224507900_B33) 2009; 11
Hallek (2022082515224507900_B15) 2010; 376
Hallek (2022082515224507900_B4) 2018; 131
Thompson (2022082515224507900_B8) 2016; 127
Hallek (2022082515224507900_B31) 2008; 111
Kwok (2022082515224507900_B7) 2016; 128
Leeksma (2022082515224507900_B17) 2021; 106
Blombery (2022082515224507900_B43) 2020; 135
Kater (2022082515224507900_B29) 2019; 37
Fürstenau (2022082515224507900_B9) 2019; 3
Baliakas (2022082515224507900_B18) 2019; 133
Thompson (2022082515224507900_B6) 2019; 134
36006672 - Blood. 2022 Aug 25;140(8):797-798
References_xml – volume: 2
  start-page: 443
  year: 2016
  end-page: 460
  ident: bib10
  article-title: Targeting BCL-2-like proteins to kill cancer cells
  publication-title: Trends Cancer.
– volume: 9
  start-page: 342
  year: 2019
  end-page: 353
  ident: bib44
  article-title: Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
  publication-title: Cancer Discov.
– volume: 133
  start-page: 1205
  year: 2019
  end-page: 1216
  ident: bib18
  article-title: Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact
  publication-title: Blood.
– volume: 127
  start-page: 279
  year: 2016
  end-page: 286
  ident: bib8
  article-title: Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL
  publication-title: Blood.
– volume: 95
  start-page: 1361
  year: 2016
  end-page: 1362
  ident: bib34
  article-title: Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia
  publication-title: Ann Hematol.
– volume: 38
  start-page: 4042
  year: 2020
  end-page: 4054
  ident: bib5
  article-title: Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO Phase III Study
  publication-title: J Clin Oncol.
– volume: 17
  start-page: 768
  year: 2016
  end-page: 778
  ident: bib13
  article-title: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
  publication-title: Lancet Oncol.
– volume: 376
  start-page: 1164
  year: 2010
  end-page: 1174
  ident: bib15
  article-title: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
  publication-title: Lancet.
– volume: 127
  start-page: 303
  year: 2016
  end-page: 309
  ident: bib20
  article-title: Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
  publication-title: Blood.
– volume: 11
  start-page: 371
  year: 2009
  end-page: 380
  ident: bib33
  article-title: Handling data below the limit of quantification in mixed effect models
  publication-title: AAPS J.
– volume: 14
  start-page: 69
  year: 2021
  ident: bib1
  article-title: Current and future treatment strategies in chronic lymphocytic leukemia
  publication-title: J Hematol Oncol.
– volume: 131
  start-page: 2745
  year: 2018
  end-page: 2760
  ident: bib4
  article-title: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
  publication-title: Blood.
– volume: 157
  start-page: 67
  year: 2012
  end-page: 74
  ident: bib14
  article-title: Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results
  publication-title: Br J Haematol.
– volume: 374
  start-page: 311
  year: 2016
  end-page: 322
  ident: bib35
  article-title: Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia
  publication-title: N Engl J Med.
– volume: 138
  start-page: 836
  year: 2021
  end-page: 846
  ident: bib42
  article-title: Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy
  publication-title: Blood.
– volume: 11
  start-page: 1929
  year: 1997
  end-page: 1932
  ident: bib39
  article-title: Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival
  publication-title: Leukemia.
– volume: 112
  start-page: 1993
  year: 2008
  end-page: 2003
  ident: bib16
  article-title: Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia
  publication-title: Blood.
– volume: 127
  start-page: 3215
  year: 2016
  end-page: 3224
  ident: bib27
  article-title: The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
  publication-title: Blood.
– volume: 18
  start-page: 109
  year: 2022
  end-page: 113
  ident: bib45
  article-title: Frontline management of CLL in 2021
  publication-title: .
– volume: 92
  start-page: 1393
  year: 2017
  end-page: 1397
  ident: bib19
  article-title: IGHV mutational status testing in chronic lymphocytic leukemia
  publication-title: Am J Hematol.
– volume: 111
  start-page: 5446
  year: 2008
  end-page: 5456
  ident: bib31
  article-title: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
  publication-title: Blood.
– volume: 3
  start-page: e287
  year: 2019
  ident: bib9
  article-title: Minimal residual disease assessment in CLL: ready for use in clinical routine?
  publication-title: HemaSphere.
– volume: 17
  start-page: 928
  year: 2016
  end-page: 942
  ident: bib36
  article-title: First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
  publication-title: Lancet Oncol.
– volume: 378
  start-page: 1107
  year: 2018
  end-page: 1120
  ident: bib30
  article-title: Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia
  publication-title: N Engl J Med.
– volume: 5
  start-page: e566
  year: 2021
  ident: bib41
  article-title: Impact of unfavorable genetics on minimal residual disease (MRD) response to venetoclax+rituximab retreatment in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): MURANO phase 3 substudy
  publication-title: HemaSphere.
– volume: 15
  start-page: 995
  year: 2009
  end-page: 1004
  ident: bib25
  article-title: The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness
  publication-title: Clin Cancer Res.
– volume: 37
  start-page: 1391
  year: 2019
  end-page: 1402
  ident: bib22
  article-title: Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia
  publication-title: J Clin Oncol.
– volume: 94
  start-page: 1848
  year: 1999
  end-page: 1854
  ident: bib12
  article-title: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia
  publication-title: Blood.
– reference: European Medicines Agency,. Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man—condition specific guidance. Vol. Rev. 2. Ref number: EMA/CHMP/703715/2012; 2016. https://www.ema.europa.eu/en/documents/scientific-guideline/evaluation-anticancer-medicinal-products-man-appendix-4-condition-specific-guidance-rev2_en.pdf. Accessed 25 May 2022.
– volume: 131
  start-page: 1910
  year: 2018
  end-page: 1919
  ident: bib40
  article-title: Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
  publication-title: Blood.
– volume: 134
  start-page: 1951
  year: 2019
  end-page: 1959
  ident: bib6
  article-title: Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy
  publication-title: Blood.
– volume: 11
  start-page: 391
  year: 2018
  end-page: 402
  ident: bib11
  article-title: Potential of BCL2 as a target for chronic lymphocytic leukemia treatment
  publication-title: Expert Rev Hematol.
– volume: 30
  start-page: 980
  year: 2012
  end-page: 988
  ident: bib3
  article-title: Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial
  publication-title: J Clin Oncol.
– volume: 39
  start-page: 2879
  year: 2021
  ident: bib32
  article-title: Venetoclax-obinutuzumab modulates clonal growth: results of a population-based minimal residual disease model from the randomized CLL14 study
  publication-title: Hematol Oncol.
– volume: 39
  start-page: 3853
  year: 2021
  end-page: 3865
  ident: bib38
  article-title: Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the Randomized Phase II CAPTIVATE Study
  publication-title: J Clin Oncol.
– volume: 358
  start-page: 15
  year: 1992
  end-page: 16
  ident: bib23
  article-title: Cancer. p53, guardian of the genome
  publication-title: Nature.
– volume: 28
  start-page: 4473
  year: 2010
  end-page: 4479
  ident: bib24
  article-title: TP53 mutation and survival in chronic lymphocytic leukemia
  publication-title: J Clin Oncol.
– volume: 36
  start-page: 1973
  year: 2018
  end-page: 1980
  ident: bib26
  article-title: Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a Phase II pivotal trial [published correction appears in
  publication-title: J Clin Oncol.
– volume: 370
  start-page: 1101
  year: 2014
  end-page: 1110
  ident: bib37
  article-title: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
  publication-title: N Engl J Med.
– volume: 7
  start-page: 4598
  year: 2016
  end-page: 4610
  ident: bib21
  article-title: Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
  publication-title: Oncotarget.
– volume: 37
  start-page: 269
  year: 2019
  end-page: 277
  ident: bib29
  article-title: Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO Phase III Study
  publication-title: J Clin Oncol.
– volume: 106
  start-page: 87
  year: 2021
  end-page: 97
  ident: bib17
  article-title: Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study
  publication-title: Haematologica.
– volume: 135
  start-page: 2402
  year: 2020
  end-page: 2412
  ident: bib28
  article-title: Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
  publication-title: Blood.
– volume: 128
  start-page: 2770
  year: 2016
  end-page: 2773
  ident: bib7
  article-title: Minimal residual disease is an independent predictor for 10-year survival in CLL
  publication-title: Blood.
– volume: 135
  start-page: 773
  year: 2020
  end-page: 777
  ident: bib43
  article-title: Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
  publication-title: Blood.
– volume: 134
  start-page: 1951
  issue: 22
  year: 2019
  ident: 2022082515224507900_B6
  article-title: Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy
  publication-title: Blood.
  doi: 10.1182/blood.2019001077
– volume: 14
  start-page: 69
  issue: 1
  year: 2021
  ident: 2022082515224507900_B1
  article-title: Current and future treatment strategies in chronic lymphocytic leukemia
  publication-title: J Hematol Oncol.
  doi: 10.1186/s13045-021-01054-w
– volume: 135
  start-page: 773
  issue: 10
  year: 2020
  ident: 2022082515224507900_B43
  article-title: Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
  publication-title: Blood.
  doi: 10.1182/blood.2019004205
– volume: 2
  start-page: 443
  issue: 8
  year: 2016
  ident: 2022082515224507900_B10
  article-title: Targeting BCL-2-like proteins to kill cancer cells
  publication-title: Trends Cancer.
  doi: 10.1016/j.trecan.2016.07.001
– volume: 7
  start-page: 4598
  issue: 4
  year: 2016
  ident: 2022082515224507900_B21
  article-title: Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.6727
– volume: 157
  start-page: 67
  issue: 1
  year: 2012
  ident: 2022082515224507900_B14
  article-title: Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results
  publication-title: Br J Haematol.
  doi: 10.1111/j.1365-2141.2011.09000.x
– volume: 127
  start-page: 303
  issue: 3
  year: 2016
  ident: 2022082515224507900_B20
  article-title: Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
  publication-title: Blood.
  doi: 10.1182/blood-2015-09-667675
– volume: 11
  start-page: 1929
  issue: 11
  year: 1997
  ident: 2022082515224507900_B39
  article-title: Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival
  publication-title: Leukemia.
  doi: 10.1038/sj.leu.2400819
– volume: 5
  start-page: e566
  year: 2021
  ident: 2022082515224507900_B41
  article-title: Impact of unfavorable genetics on minimal residual disease (MRD) response to venetoclax+rituximab retreatment in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): MURANO phase 3 substudy
  publication-title: HemaSphere.
– volume: 15
  start-page: 995
  issue: 3
  year: 2009
  ident: 2022082515224507900_B25
  article-title: The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-08-1630
– volume: 135
  start-page: 2402
  issue: 26
  year: 2020
  ident: 2022082515224507900_B28
  article-title: Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
  publication-title: Blood.
  doi: 10.1182/blood.2019004492
– volume: 127
  start-page: 279
  issue: 3
  year: 2016
  ident: 2022082515224507900_B8
  article-title: Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL
  publication-title: Blood.
  doi: 10.1182/blood-2015-08-634816
– volume: 112
  start-page: 1993
  issue: 5
  year: 2008
  ident: 2022082515224507900_B16
  article-title: Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia
  publication-title: Blood.
  doi: 10.1182/blood-2007-07-099432
– volume: 374
  start-page: 311
  issue: 4
  year: 2016
  ident: 2022082515224507900_B35
  article-title: Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1513257
– volume: 376
  start-page: 1164
  issue: 9747
  year: 2010
  ident: 2022082515224507900_B15
  article-title: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(10)61381-5
– volume: 370
  start-page: 1101
  issue: 12
  year: 2014
  ident: 2022082515224507900_B37
  article-title: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1313984
– volume: 131
  start-page: 1910
  issue: 17
  year: 2018
  ident: 2022082515224507900_B40
  article-title: Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
  publication-title: Blood.
  doi: 10.1182/blood-2017-10-810044
– volume: 36
  start-page: 1973
  issue: 19
  year: 2018
  ident: 2022082515224507900_B26
  article-title: Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a Phase II pivotal trial
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2017.76.6840
– volume: 111
  start-page: 5446
  issue: 12
  year: 2008
  ident: 2022082515224507900_B31
  article-title: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
  publication-title: Blood.
  doi: 10.1182/blood-2007-06-093906
– volume: 17
  start-page: 928
  issue: 7
  year: 2016
  ident: 2022082515224507900_B36
  article-title: First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)30051-1
– volume: 94
  start-page: 1848
  issue: 6
  year: 1999
  ident: 2022082515224507900_B12
  article-title: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia
  publication-title: Blood.
  doi: 10.1182/blood.V94.6.1848
– volume: 95
  start-page: 1361
  issue: 8
  year: 2016
  ident: 2022082515224507900_B34
  article-title: Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia
  publication-title: Ann Hematol.
  doi: 10.1007/s00277-016-2695-x
– volume: 39
  start-page: 3853
  issue: 34
  year: 2021
  ident: 2022082515224507900_B38
  article-title: Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the Randomized Phase II CAPTIVATE Study
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.21.00807
– volume: 11
  start-page: 371
  issue: 2
  year: 2009
  ident: 2022082515224507900_B33
  article-title: Handling data below the limit of quantification in mixed effect models
  publication-title: AAPS J.
  doi: 10.1208/s12248-009-9112-5
– volume: 38
  start-page: 4042
  issue: 34
  year: 2020
  ident: 2022082515224507900_B5
  article-title: Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO Phase III Study
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.20.00948
– volume: 9
  start-page: 342
  issue: 3
  year: 2019
  ident: 2022082515224507900_B44
  article-title: Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-1119
– volume: 128
  start-page: 2770
  issue: 24
  year: 2016
  ident: 2022082515224507900_B7
  article-title: Minimal residual disease is an independent predictor for 10-year survival in CLL
  publication-title: Blood.
  doi: 10.1182/blood-2016-05-714162
– volume: 358
  start-page: 15
  issue: 6381
  year: 1992
  ident: 2022082515224507900_B23
  article-title: Cancer. p53, guardian of the genome
  publication-title: Nature.
  doi: 10.1038/358015a0
– volume: 133
  start-page: 1205
  issue: 11
  year: 2019
  ident: 2022082515224507900_B18
  article-title: Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact
  publication-title: Blood.
  doi: 10.1182/blood-2018-09-873083
– volume: 28
  start-page: 4473
  issue: 29
  year: 2010
  ident: 2022082515224507900_B24
  article-title: TP53 mutation and survival in chronic lymphocytic leukemia
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2009.27.8762
– year: 2016
  ident: 2022082515224507900_B2
  article-title: Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man—condition specific guidance
– volume: 30
  start-page: 980
  issue: 9
  year: 2012
  ident: 2022082515224507900_B3
  article-title: Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2011.36.9348
– volume: 18
  start-page: 109
  issue: 2
  year: 2022
  ident: 2022082515224507900_B45
  article-title: Frontline management of CLL in 2021
  publication-title: JCO Oncol Pract.
  doi: 10.1200/OP.21.00258
– volume: 37
  start-page: 1391
  issue: 16
  year: 2019
  ident: 2022082515224507900_B22
  article-title: Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.18.01460
– volume: 11
  start-page: 391
  issue: 5
  year: 2018
  ident: 2022082515224507900_B11
  article-title: Potential of BCL2 as a target for chronic lymphocytic leukemia treatment
  publication-title: Expert Rev Hematol.
  doi: 10.1080/17474086.2018.1456332
– volume: 127
  start-page: 3215
  issue: 25
  year: 2016
  ident: 2022082515224507900_B27
  article-title: The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
  publication-title: Blood.
  doi: 10.1182/blood-2016-01-688796
– volume: 106
  start-page: 87
  issue: 1
  year: 2021
  ident: 2022082515224507900_B17
  article-title: Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study
  publication-title: Haematologica.
  doi: 10.3324/haematol.2019.239947
– volume: 92
  start-page: 1393
  issue: 12
  year: 2017
  ident: 2022082515224507900_B19
  article-title: IGHV mutational status testing in chronic lymphocytic leukemia
  publication-title: Am J Hematol.
  doi: 10.1002/ajh.24808
– volume: 131
  start-page: 2745
  issue: 25
  year: 2018
  ident: 2022082515224507900_B4
  article-title: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
  publication-title: Blood.
  doi: 10.1182/blood-2017-09-806398
– volume: 3
  start-page: e287
  issue: 5
  year: 2019
  ident: 2022082515224507900_B9
  article-title: Minimal residual disease assessment in CLL: ready for use in clinical routine?
  publication-title: HemaSphere.
  doi: 10.1097/HS9.0000000000000287
– volume: 17
  start-page: 768
  issue: 6
  year: 2016
  ident: 2022082515224507900_B13
  article-title: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)30019-5
– volume: 37
  start-page: 269
  issue: 4
  year: 2019
  ident: 2022082515224507900_B29
  article-title: Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO Phase III Study
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.18.01580
– volume: 378
  start-page: 1107
  issue: 12
  year: 2018
  ident: 2022082515224507900_B30
  article-title: Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1713976
– volume: 39
  start-page: hon.31_2879
  year: 2021
  ident: 2022082515224507900_B32
  article-title: Venetoclax-obinutuzumab modulates clonal growth: results of a population-based minimal residual disease model from the randomized CLL14 study
  publication-title: Hematol Oncol.
  doi: 10.1002/hon.31_2879
– volume: 138
  start-page: 836
  issue: 10
  year: 2021
  ident: 2022082515224507900_B42
  article-title: Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy
  publication-title: Blood.
  doi: 10.1182/blood.2020009578
– reference: 36006672 - Blood. 2022 Aug 25;140(8):797-798
SSID ssj0014325
Score 2.649271
Snippet The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or...
Kater and colleagues report on 5-year outcomes for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) when treated with fixed-duration...
SourceID pubmedcentral
hal
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 839
SubjectTerms Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Bendamustine Hydrochloride
Bendamustine Hydrochloride - adverse effects
Bridged Bicyclo Compounds, Heterocyclic
Bridged Bicyclo Compounds, Heterocyclic - adverse effects
Clinical Trials and Observations
Hematology
Human health and pathology
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Life Sciences
Neoplasm, Residual
Neoplasm, Residual - drug therapy
Neoplasm, Residual - etiology
Recurrence
Rituximab
Rituximab - adverse effects
Sulfonamides
Title Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
URI https://dx.doi.org/10.1182/blood.2021015014
https://www.ncbi.nlm.nih.gov/pubmed/35605176
https://www.proquest.com/docview/2668911580
https://hal.science/hal-04547301
https://pubmed.ncbi.nlm.nih.gov/PMC9412011
Volume 140
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9tAEF6clKZ5Ka3Tw73YlrZQimLrquRHN3UwjVNoSSBvYrVaYYEtCVsKbn59Z1a7luQctH0RQscuaD7Nzux8M0PIezSRXcFDY8A8ZjjDiBvMjGKDOa7FuPAF6AdkW_z4Mjl3vl-4F53OZYO1VBbhIb-6Ma_kf6QK10CumCX7D5LdDAoX4BzkC0eQMBz_SsbjVGUZYiYYRgNkHtQpuHW4HV7m6M1Hn7OygMkl8UqmruQr3OA8hqVxKZvtgFKYTlWz8DhZi8iAUStcoCYsMj5na2OZFOU6WbCwFQaeq17zFWUY9xGWmuBbc4ZPkjxvsJHqSNQ44bNZtqzSTlTko37t2wfL-5VdgTOfbfi8zU0K8G8HvlElNB8KpVixEvbAGrQ0b1WpSUHMb-hRv6pwdF2_-1gvVnL6wbcHd9XEuGjzUZBQvpDytsGYc01vq9B2tXSrWzvkngXuBXa-OPlZR58c23J1SNu3-tvT7ZM9PcBt1szODGm1132Wbeptw5Y5e0QeKieEjipEPSYdkXbJwShlRbb4TT9SSQuW8ZYuuf9Vnz040s0Bu2TvVHEyDshKo5A2UUgBhRRQSBUKqUYhTVKqUdivMUgBg1RikLYxSG_C4BNyfjw-O5oYqpWHwV3HK4zYtr3Yilg05BbzwKx1HWG7IXIsGfjMlmDwSSxuc-bZHvPAC4gcl_tOyMGfCofcfkp20ywVzwl1hpyFYGNFURw6YSgYLkpYbzs2bcYGdo_0tUgCrurcY7uVeSD9Xd8KpDyDWp498mnzRl7VeLnjWVtLOVA2amV7BgDRO956B4DYDI4l3SejaYDXsAQmrrKXZo-81XgJQJoYuGOpyMpVAEa0D0aJ6w965FmFn81YGok94rWQ1ZqsfSdNZrKO_NAx0fx_ceuYL8l-_TO_IrvFshSvwQYvwjfyh_kDaHHfTQ
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enduring+undetectable+MRD+and+updated+outcomes+in+relapsed%2Frefractory+CLL+after+fixed-duration+venetoclax-rituximab&rft.jtitle=Blood&rft.au=Seymour%2C+John+F&rft.au=Kipps%2C+Thomas+J&rft.au=Eichhorst%2C+Barbara+F&rft.au=D%27Rozario%2C+James&rft.date=2022-08-25&rft.eissn=1528-0020&rft.volume=140&rft.issue=8&rft.spage=839&rft_id=info:doi/10.1182%2Fblood.2021015014&rft_id=info%3Apmid%2F35605176&rft.externalDocID=35605176
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon